An FDA AdCom voted for a new intermediate endpoint of MRD for accelerated approvals in multiple myeloma in 2024.

Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...

TPD technologies, particularly PROTACs and MGDs, represent a paradigm shift in drug development by completely eliminating ...

Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by the loss of function of the maternally inherited ...

US pharma major Bristol Myers Squibb has announced that the Phase III EXCALIBER-RRMM study evaluating iberdomide, an ...

Iberdomide, which is being positioned as a successor to Revlimid, will continue in EXCALIBER-RRMM as the study progresses to ...

Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD™), combined with standard ...

Iberdomide is a member of a new drug class in myeloma known as CELMoD agents, which build on the established platform of ...

The EXCALIBER-RRMM study evaluated the efficacy and safety of iberdomide, an investigational cereblon E3 ligase modulator, in combination with dexamethasone and daratumumab in adults with RRMM.

TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein ...

Monte Rosa Therapeutics stock surged after expanding its Novartis partnership. Click here to learn about their innovative ...